Evogene Ltd. (EVGN)’s Stock Is Sell After Touching 52-Week Low

December 26, 2017 - By Marie Mckinney

The stock of Evogene Ltd. (NASDAQ:EVGN) hit a new 52-week low and has $3.19 target or 5.00 % below today’s $3.36 share price. The 9 months bearish chart indicates high risk for the $89.41M company. The 1-year low was reported on Dec, 26 by Barchart.com. If the $3.19 price target is reached, the company will be worth $4.47M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 0.90% or $0.03 during the last trading session, reaching $3.36. About 14,400 shares traded. Evogene Ltd. (NASDAQ:EVGN) has declined 23.47% since December 26, 2016 and is downtrending. It has underperformed by 40.17% the S&P500.

Analysts await Evogene Ltd. (NASDAQ:EVGN) to report earnings on February, 26. They expect $-0.18 earnings per share, up 30.77 % or $0.08 from last year’s $-0.26 per share. After $-0.20 actual earnings per share reported by Evogene Ltd. for the previous quarter, Wall Street now forecasts -10.00 % EPS growth.

More notable recent Evogene Ltd. (NASDAQ:EVGN) news were published by: Globenewswire.com which released: “Evogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers” on February 14, 2017, also Businesswire.com with their article: “Evogene Announces Successful Completion of First Computational Discovery of …” published on August 04, 2015, Globenewswire.com published: “Evogene Announces Revised and Expanded Market Focus and New Corporate Structure” on October 30, 2017. More interesting news about Evogene Ltd. (NASDAQ:EVGN) were released by: Globenewswire.com and their article: “Evogene to Present Innovative Approach for Improving Cannabis for Medical …” published on March 07, 2017 as well as Globenewswire.com‘s news article titled: “Evogene to Transfer Stock Exchange Listing to NASDAQ” with publication date: December 19, 2016.

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. The company has market cap of $89.41 million. It operates through two divisions, Evogene and Evofuel. It currently has negative earnings. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: